Acrivon Therapeutics, Inc. Segments Disclosure
12. Segment Information
The Company manages its operations as a operating and reportable segment focused on the research and development of precision oncology therapies. The accounting policies of the single reportable segment are identical to those described in Note 2. The chief operating decision maker, who manages the Company’s operations on a consolidated basis, assesses performance for the reportable segment using consolidated net loss to monitor budget versus actual results and to determine how to effectively allocate the Company’s resources. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The following table presents certain financial data including significant segment expenses for the Company’s reportable segment for the years ended December 31, 2025 and 2024 (in thousands):
|
|
Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
ACR-368 direct research and development expenses |
|
$ |
23,035 |
|
|
$ |
34,135 |
|
ACR-2316 direct research and development expenses1 |
|
|
7,523 |
|
|
|
3,384 |
|
Other drug discovery programs direct research and development expenses |
|
|
2,294 |
|
|
|
4,037 |
|
Personnel related indirect research and development expenses |
|
|
21,816 |
|
|
|
18,184 |
|
Facilities, supplies and other indirect research and development expenses |
|
|
5,322 |
|
|
|
4,252 |
|
General and administrative expenses |
|
|
24,124 |
|
|
|
25,207 |
|
Other segment items2 |
|
|
(6,209 |
) |
|
|
(8,643 |
) |
Net loss |
|
$ |
(77,905 |
) |
|
$ |
(80,556 |
) |
1 ACR-2316 direct research and development expenses include costs related to the Company’s novel, internally-discovered second clinical-stage asset, which was promoted to a development program upon being granted IND clearance in the third quarter of 2024 and includes clinical trial and related activities. Prior to IND clearance, costs related to preclinical drug discovery activities progression related to ACR-2316 were included in other drug discovery programs direct research and development expenses.
2 Other segment items consist of interest income and other income (expense), net. Interest income consists of interest income earned on cash equivalents and investments and amortization of premiums and accretion of discounts to maturity for available-for-sale debt securities. Other income (expense), net primarily consists of realized and unrealized gains and losses on foreign currency transactions, state taxes, and investment management fees.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 19, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.